PTPRC and cancer: An obviously decreased absolute numbers were observed in cancer patients, including CD45+, CD3+ T, CD3+CD4+ Th, CD3+CD8+ CTL, CD16+CD56+ NK and CD19+ B cells (P < 0.0001).